The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
 
Hiroyuki Arai
No Relationships to Disclose
 
Yan Yang
No Relationships to Disclose
 
Joshua Millstein
No Relationships to Disclose
 
Tadamichi Denda
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Daiichi-Sankyo; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
 
Fang-Shu Ou
Consulting or Advisory Role - SC Liver Research Consortium
 
Federico Innocenti
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
Honoraria - Tempus
Consulting or Advisory Role - Emerald Lake Safety; Symberix
Patents, Royalties, Other Intellectual Property - United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain MJ, Innocenti F, Iyer L. Filed on April 12, 2001, serial number 09/835,082.; United States Patent: “Methods of identifying risk of bevacizumab-induced proteinuria and hypertension”, Innocenti F, Quintanilha J, Lin D, Owzar K, Wang J. Filed on July 17, 2020, serial number 16/932,002.; United States Patent: “Optimization of cancer treatment with irinotecan”, Ratain MJ, Innocenti F, Karabatsos P, Grimsley C, Di Rienzo A. Filed on February 12, 2003, serial number 60/446,942.; United States Provisional Patent Application: “Plasma Levels of Angiopoietin-2, VEGF-A, And VCAM-1 as Markers of Bevacizumab Induced Hypertension”, Innocenti F, Quintanilha J. Filed on April 1, 2021, serial number 63/169,301.
Travel, Accommodations, Expenses - Abbvie
 
Hiroyuki Takeda
Honoraria - Bristol-Myers Squibb Japan; Taiho Pharmaceutical
 
Ayako Doi
Honoraria - Taiho Pharmaceutical
 
Yoshiki Horie
No Relationships to Disclose
 
Kumiko Umemoto
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
 
Naoki Izawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Guardant Health; Kissei Pharmaceutical; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Jingyuan Wang
No Relationships to Disclose
 
Francesca Battaglin
Travel, Accommodations, Expenses - Caris Life Sciences
 
Natsuko Kawanishi
No Relationships to Disclose
 
Priya Jayachandran
No Relationships to Disclose
 
Shivani Soni
No Relationships to Disclose
 
Zhang Wu
No Relationships to Disclose
 
Alan P. Venook
Consulting or Advisory Role - Amgen; BridgeBio Pharma; Exelixis; GlaxoSmithKline; Merck Sharp & Dohme
Research Funding - Amgen
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono